Form 4: ProMIS Neurosciences Director Receives Stock Options
Statement of Changes in Beneficial Ownership
Director Paul Alex Slanix was granted stock options for 16,500 common shares of ProMIS Neurosciences Inc.
Summary
- Director Paul Alex Slanix received two grants of stock options on May 20, 2026.
- The first grant consists of 5,500 options with an exercise price of $10.77, vesting in full on May 20, 2027.
- The second grant consists of 11,000 options with an exercise price of $10.77, with 25% vesting immediately and the remainder vesting ratably over 36 months.
- Both option grants have an expiration date of May 20, 2036.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral for the stock price.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
Negatives
- Potential future dilution of existing shareholders upon the exercise of these options.
Risks
- The value of the options is dependent on the future market performance of ProMIS Neurosciences common shares.
Future Outlook
The options vest over a period extending to May 2027 and beyond, indicating a long-term retention and incentive strategy for the director.
Industry Context
StockSavvy.ai notes that equity grants to directors are standard practice in the biotechnology sector to ensure board members remain incentivized to oversee long-term clinical and commercial development.
Comparison to Industry Standards
- The use of multi-year vesting schedules for director options is consistent with standard corporate governance practices in the life sciences industry.
- The exercise price reflects the market value at the time of grant, aligning with typical regulatory and compensation committee requirements.
Stakeholder Impact
- Shareholders may experience minor dilution if these options are exercised in the future.
Next Steps
- Vesting of 25% of the 11,000 share grant occurred on May 20, 2026.
- Continued service on the Board is required for the remaining options to vest.
Key Dates
| Date | Description |
|---|---|
| 05/20/2026 | Date of option grant and earliest transaction. |
| 05/20/2027 | Full vesting date for the 5,500 share option grant. |
| 05/20/2036 | Expiration date for all granted options. |
Keywords
ProMIS Neurosciences, PMN, Form 4, Insider Trading, Stock Options, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.